Drug Search Results
More Filters [+]

Gabexate

Alternative Names: gabexate
Latest Update: 2023-08-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: SP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Korea | Taiwan | Ukraine

Approved Indications: None

Known Adverse Events: None

Company: Yonsei University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Gabexate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Reperfusion Injury|Sepsis|Small Cell Carcinoma|Liver Failure, Acute|Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR-IPR-14005518

N/A

Not yet recruiting

Pancreatitis, Acute

2017-12-31

NCT02710266

P3

Terminated

Reperfusion Injury|Hepatocellular Carcinoma|Liver Failure, Acute|Sepsis|Small Cell Carcinoma

2017-02-25

Recent News Events